Captura Biopharma
Little Rock
About Captura Biopharma
Captura Biopharma is an biotechnology company engaged in the development and commercialization of heavy metal chelators useful in the treatment of internal radionuclide contamination and heavy metal poisoning. Its lead chelation candidate, C2E2, will be the world's first oral treatment indicated for internal radiation contamination and has been proven in efficacy studies to target select heavy metals, notably americium, plutonium, and lead. Heavy metal contamination, including exposure to transuranic elements, is on the rise.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $50.0M
- Last round: Series Unknown (Aug 2021)
- Website: capturabiopharma.com
- Phone: 501-516-3905
Industries & Categories
Biopharma, Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/captura-biopharma-140554 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.